Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The report serves as a notification of a directorate change and confirms compliance with Listing Rule 9.6.13R.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance update and does not contain financial performance data.
Material Changes
The filing confirms the appointment of Mr. Urs Rohner as a Non-Executive Director and member of GSK's Remuneration Committee, effective January 1, 2015. This follows an initial announcement made on October 3, 2014. The company states there are no further disclosures required regarding this matter.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The scope is limited to the confirmation of the board appointment.
Key Facts for Investor Verification
- Mr. Urs Rohner is appointed as a Non-Executive Director effective January 1, 2015.
- Mr. Rohner will serve on the Remuneration Committee.
- The filing confirms no additional disclosures are required under Listing Rule 9.6.13R.
- No financial data is included in this specific report.